The FDA approves a treatment for stage III mismatch repair-deficient colon cancer, and age-based testing criteria could miss nearly three-quarters of patients with inherited cancer-risk mutations.

by Thomas Celona

Colorectal cancer diagnoses in teens and young adults are often caught at advanced stages, and 1 in 8 cancers is linked to an infection, which is often preventable.

by Eric Fitzsimmons

Radiation delivered over several sessions reduced recurrence for large brain metastases, and an experimental SERD may delay progression in estrogen receptor-positive breast cancer.

by Darlene Dobkowski

An FDA committee supports a liquid biopsy that screens for up to 50 cancers, and the FDA approves a drug combo for certain people with breast cancer.

by Thomas Celona

MRI surveillance for brain metastases helps preserve cognition in small cell lung cancer, and an AACR report calls for sustained research funding.

by Eric Fitzsimmons

Cancer care aid enrollments for people near the World Trade Center site tripled in recent years, and the FDA approved an oral SERD for ESR1-mutated breast cancer.

by Darlene Dobkowski

The FDA approves two therapies to treat rare blood cancers, and U.S. cervical cancer screening rates decline.

by Thomas Celona

The FDA approves a RAS-targeted therapy, and government-funded research explores topics often neglected by industry trials.

by Eric Fitzsimmons

An mRNA vaccine with immunotherapy may lower recurrence in melanoma, and active surveillance for prostate cancer has increased in the Veterans Affairs health system over the last two decades.

by Darlene Dobkowski

Patients are waiting longer to start treatment than they did a decade ago, and an experimental pancreatic cancer drug is reaching patients ahead of FDA approval.

by Marci Landsmann